Answer Key: The Liver–Brain Connection: Understanding Metabolic Pathways in Alzheimer Disease
Answer Key:
1. True or false: Impaired hepatic function in conditions such as nonalcoholic fatty liver disease (NAFLD) contributes to cognitive decline primarily through reduced bile acid synthesis.
Correct Answer: False
NAFLD and related metabolic-associated fatty liver disease (MASLD) are increasingly recognized as key contributors to neurodegeneration through chronic systemic inflammation. Hepatic steatosis leads to lipotoxicity, oxidative stress, and infiltration of immune cells into liver tissue, which triggers the sustained release of inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). These cytokines enter systemic circulation and compromise the blood-brain barrier (BBB), promoting microglial activation and neuroinflammatory cascades within the central nervous system. Chronic low-grade inflammation alters endothelial integrity and cerebral microvasculature, ultimately causing neuronal damage, synaptic dysfunction, and cognitive impairment. In this way, hepatic inflammation acts as a peripheral driver of central neurodegeneration, bridging liver pathology with AD–related processes such as amyloid-β (Aβ) accumulation and tau pathology.
2. Which hepatokine has been shown to cross the blood-brain barrier (BBB) and modulate both Aβ and tau pathology?
Correct Answer: FGF-21
FGF-21 is a liver-derived hormone-like protein that exerts both metabolic and neuroprotective effects. Experimental models demonstrate that FGF-21 can cross the BBB with notable efficiency, retaining approximately 70% of its molecular integrity in brain parenchyma within minutes of systemic administration. Once in the central nervous system, FGF-21 acts on neuronal and glial cells to mitigate Alzheimer pathology through multiple pathways. It decreases Aβ plaque deposition and inhibits tau hyperphosphorylation by activating signaling cascades such as PI3K/AKT/GSK-3β and PP2A/MAPK/HIF-1α. In addition, it enhances brain-derived neurotrophic factor (BDNF) expression, promoting synaptic resilience and neuronal survival. FGF-21 also exhibits potent anti-inflammatory properties—suppressing M1-type microglial activation and downregulating pro-inflammatory cytokine production via NF-κB inhibition. Clinically, low circulating levels of FGF-21 have been reported in patients with AD, suggesting its potential as a diagnostic biomarker and therapeutic target to counter metabolic and neuroinflammatory dysfunctions linked to AD.
3. True or false: The liver-derived biomarker higher fetuin-A has been positively correlated with better cognitive performance in clinical studies.
Correct Answer: False
Fetuin-A, a glycoprotein predominantly synthesized in hepatocytes, functions as an anti-inflammatory and antioxidative modulator that plays a significant role in metabolic and neurological health. In the context of AD, plasma Fetuin-A levels have been found to positively correlate with Mini-Mental State Examination (MMSE) scores and overall cognitive performance. Mechanistically, Fetuin-A inhibits inflammatory mediators such as high-mobility group box 1 (HMGB1) and suppresses TGF-β signaling, both of which are implicated in neuroinflammation and neuronal injury. Reduced Fetuin-A levels are observed in AD and are associated with greater cognitive decline, likely reflecting impaired hepatic synthetic function and increased BBB permeability that diminishes the protein’s neuroprotective availability. Moreover, phosphorylated Fetuin-A can cross a compromised BBB, suggesting that peripheral deficits may translate directly into central vulnerability. Thus, maintaining adequate Fetuin-A levels may mitigate neuroinflammatory processes and support cognitive resilience in individuals at risk for or living with AD.
Reference:
Song D, Li Y, Yang LL, Luo YX, Yao XQ. Bridging systemic metabolic dysfunction and Alzheimer's disease: the liver interface. Mol Neurodegener. 2025;20(1):61. Published 2025 May 28. doi:10.1186/s13024-025-00849-6